SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

AIM ImmunoTech CEO Equels Acquires $6,550 in Common Shares

CEO and President Thomas K. Equels acquired $6,550 in AIM ImmunoTech common shares.

AIM

Related stories